Nicholson Wealth Management Group LLC Has $1.84 Million Holdings in Zoetis Inc. $ZTS

Nicholson Wealth Management Group LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 45.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,654 shares of the company’s stock after purchasing an additional 4,596 shares during the period. Nicholson Wealth Management Group LLC’s holdings in Zoetis were worth $1,844,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. CIBC Asset Management Inc grew its stake in shares of Zoetis by 4.3% during the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after purchasing an additional 10,434 shares during the period. Nordea Investment Management AB grew its stake in shares of Zoetis by 79.2% during the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after purchasing an additional 2,179,578 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Zoetis by 134.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after purchasing an additional 935,432 shares during the period. Mitsubishi UFJ Trust & Banking Corp grew its stake in shares of Zoetis by 6.5% during the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after purchasing an additional 18,040 shares during the period. Finally, Seilern Investment Management Ltd grew its stake in shares of Zoetis by 361.2% during the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after purchasing an additional 261,155 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Down 0.2%

NYSE:ZTS opened at $120.81 on Thursday. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a market cap of $50.82 billion, a price-to-earnings ratio of 20.07, a PEG ratio of 1.85 and a beta of 0.98. The stock has a 50-day moving average price of $121.98 and a two-hundred day moving average price of $126.70.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same period in the previous year, the firm earned $1.40 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is presently 35.22%.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of analyst reports. UBS Group set a $136.00 price objective on Zoetis in a research note on Thursday, January 29th. Morgan Stanley set a $160.00 price objective on Zoetis in a research note on Thursday, December 18th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Citigroup started coverage on Zoetis in a research note on Wednesday. They issued a “buy” rating and a $145.00 target price for the company. Finally, William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus price target of $152.25.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.